Tworoger Shelley S, Hankinson Susan E
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave., 3rd Floor, Boston, Massachusetts 02115, USA.
Cancer Causes Control. 2006 Sep;17(7):889-99. doi: 10.1007/s10552-006-0035-5.
The inclusion of biomarkers measured on the continuous scale, such as endogenous sex hormones or antioxidant levels, has become common in epidemiologic studies, and introduces additional sources of error that are specific to biomarkers. This includes error associated with specimen collection, processing, and storage; laboratory error (both within and between batch); and variability in the biomarker levels over time within an individual. In this review, we discuss and recommend study design and analytic strategies to deal with these sources of measurement error. In particular we describe methods to prevent or minimize some sources of error through appropriate sample collection and storage, communication with the laboratory, proper batching of samples, and participant matching. We also discuss how to quantify error related to biomarkers, focusing on issues of quality control, pilot studies, and how to measure within-person stability over time. Further, we discuss analytic issues for dealing with laboratory and within-person variability. Finally we recommend that journals standardize the reporting of biomarker assays in scientific manuscripts.
在流行病学研究中,纳入以连续尺度测量的生物标志物,如内源性性激素或抗氧化剂水平,已变得很常见,这引入了特定于生物标志物的额外误差来源。这包括与样本采集、处理和储存相关的误差;实验室误差(批次内和批次间);以及个体内生物标志物水平随时间的变异性。在本综述中,我们讨论并推荐研究设计和分析策略来处理这些测量误差来源。特别是,我们描述了通过适当的样本采集和储存、与实验室沟通、样本的正确批次处理以及参与者匹配来预防或最小化某些误差来源的方法。我们还讨论了如何量化与生物标志物相关的误差,重点关注质量控制、预试验研究以及如何测量个体内随时间的稳定性。此外,我们讨论了处理实验室和个体内变异性的分析问题。最后,我们建议期刊在科学稿件中规范生物标志物测定的报告。